American Board of Obesity Medicine

Short answer Many people see noticeable weight loss within weeks and substantial loss over months, but how fast and how much varies a lot by drug, dose, starting weight, and behavior. With GLP‑1/GIP drugs you usually need ongoing treatment (or very intensive lifestyle/behavior changes) to keep the weight off — stopping the drug commonly leads to regain. What the clinical trials show (typical ranges) Semaglutide for obesity (Wegovy® 2.4 mg weekly): average ~10–15% body‑weight loss after ~68 weeks in trials (STEP program). Most people lose steadily over the first 6–12 months. Semaglutide for diabetes (Ozempic® 0.5–1.0 mg weekly): smaller average loss (~4–6%) because dose/setting differ. Tirzepatide (Mounjaro® for diabetes; Zepbound® for weight): larger average losses in obesity trials — roughly 15–21% at ~72 weeks depending on dose (higher doses -> more weight loss). Timeline: you commonly see early losses within the first 4–12 weeks, a larger chunk within the first 3–6 months, and continued loss up to about 12–18 months in trials. Why people differ Starting weight and body composition, dose achieved, how well you tolerate the drug (GI side effects often limit dose), how strictly you change eating/exercise habits, other medicines or conditions, and genetics all affect results. Individual responses range from very little to >20% body‑weight loss. Sustainability GLP‑1/GIP drugs change appetite, satiety and some metabolic parameters while you take them; they do not “rewire” every biological driver of weight permanently. In trial extensions and withdrawal studies, many people regained much of the lost weight when the drug was stopped. Best chance to sustain loss: continue medication as recommended by your clinician AND work on long‑term behavioral changes (structured nutrition plan, physical activity, sleep, stress management, and often behavioral counseling). Some people stay on these medicines long term under medical supervision. Risks and monitoring Common: nausea, vomiting, diarrhea, constipation, early satiety. Less common/serious: gallbladder disease, pancreatitis (rare), increases in heart rate, and there are contraindications (personal or family history of certain thyroid cancers, MEN2). You need baseline and periodic follow‑up with a prescriber. What to do next / Questions to ask your clinician Which drug and dose is appropriate for me (Wegovy vs Ozempic vs Mounjaro vs Zepbound)? What weight loss target is reasonable in 3, 6, and 12 months? How long should I expect to take it? If I stop, what’s the plan to prevent regain? How will side effects be managed? What monitoring is needed? Brands/services to consider (talk to your clinician) Wegovy® (semaglutide 2.4 mg) — approved specifically for chronic weight management and backed by large obesity trials. Zepbound® (tirzepatide for weight) — newer, showed very large average weight loss in obesity trials. Mounjaro® (tirzepatide for diabetes) and Ozempic® (semaglutide for diabetes) — used for diabetes but often discussed with clinicians for weight effects (doses/indications differ). See an obesity medicine specialist or a multidisciplinary weight‑loss clinic (look for clinicians certified by the American Board of Obesity Medicine or centers that offer medical, nutritional, and behavioral support) — combining medication with structured support gives better long‑term outcomes. Bottom line You can often lose substantial weight on GLP‑1/GIP medicines over months (commonly 10–20% in obesity trials for the most effective agents/doses), but long‑term maintenance usually requires ongoing therapy or intensive lifestyle/behavioral strategies. Discuss risks, expected timeline, and a stopping/maintenance plan with a prescriber before starting. If you want, tell me your age, current weight/height, medical conditions and whether you have a preference between semaglutide or tirzepatide — I can give a more personalized expectation and a list of questions to bring to your doctor.

Mentioned in position 5 of 5

Good question — telehealth clinics vary a lot in how safely and effectively they prescribe Wegovy (semaglutide). Before you pay, verify these things and ask the provider these specific questions. What to check (quick checklist) Clinician qualifications and licensing Is the prescriber licensed in your state? Will an MD/DO or an NP/PA with obesity/endo experience manage your care? Do they have board certification or formal experience in obesity medicine (American Board of Obesity Medicine or endocrinology preferred)? Medical evaluation and safety screening Will they take a full medical history, current meds, and allergy list? Do they screen for contraindications (personal/family history of medullary thyroid carcinoma or MEN2) and pregnancy (pregnancy test and contraception counseling for people who can become pregnant)? Will they check baseline labs (basic metabolic panel, A1c if diabetic risk, liver tests as indicated)? Follow-up, monitoring, and titration plan Is there a clear written titration schedule for Wegovy (how doses escalate and when)? How often are follow-ups scheduled during titration and maintenance (phone/video or messaging)? Who manages side effects and how do you contact them between visits? Comprehensive care (not just a prescription) Does the program include nutrition counseling, behavior change coaching, or a structured plan to support lifestyle changes? Are dietitians, therapists, or exercise specialists part of care or available as add‑ons? Cost transparency and insurance help Do they give a full breakdown up front: visit fees, program fees, lab costs, shipping, and expected drug cost? Will they submit prior authorization paperwork to your insurer or help enroll in manufacturer savings programs? Do they use a specialty pharmacy, or do they send prescriptions to a retail pharmacy? (Wegovy often is handled as a specialty medication.) Dispensing, shipping, and storage How is the medicine shipped (refrigerated packaging)? Is there tracking and signature required? What is their refill process and delivery timing? Coordination and record-keeping Will they share visit notes and prescriptions with your primary care provider (with permission)? Refunds, cancellations, and continuity What is their refund/cancellation policy if the med is denied by insurance or you decide not to continue? Privacy and legal Is the service HIPAA-compliant and do they have clear patient consent forms? Reputation and outcomes Look for patient reviews, Better Business Bureau/Trustpilot ratings, and evidence of program outcomes (not exaggerated promises). Red flags (avoid these) Promises of extreme or guaranteed weight loss. Prescriptions issued after a very short questionnaire or phone call with no documented medical review. No plan for lab monitoring, follow-up, or side-effect management. Pressure to buy multiple months’ supply upfront without an evaluation. No transparent pricing or inability to explain insurance/prior authorization path. Telehealth services to consider (check current availability/pricing) Calibrate — obesity-focused, structured metabolic program with long-term coaching and clinical oversight; known for comprehensive approach (higher cost). Found — direct-to-consumer GLP-1 programs (semaglutide/tirzepatide available at times), flexible pricing and frequent coaching options. PlushCare — general telehealth that can manage weight-loss medications and may assist with insurance/prescriptions; convenient for ongoing medical follow-up. Hims & Hers — consumer-facing telehealth that has offered GLP-1 access and user-friendly platforms; verify clinician oversight and state availability. Ro (Roman) — large telehealth provider with weight-loss offerings; check whether they currently prescribe Wegovy in your state. (Availability of semaglutide/Wegovy varies by company and by state — confirm on each site.) Questions to ask them before you pay “Who will be my prescriber and are they licensed and experienced in obesity medicine?” “What baseline tests do you require, and who pays for them?” “What is the full monthly cost including the medication, shipping, lab work, and visits? Are there any extra fees?” “Will you handle prior authorization and appeals with my insurer?” “What is the exact titration schedule and follow-up cadence? How do I reach clinical staff between visits?” “What is your refund/cancellation policy if insurance denies the drug or I change my mind?” “How is the medication shipped and stored? Which pharmacy will dispense it?” If you want, tell me your state and whether you plan to use insurance — I can check which of the named providers currently operate in your area and give more tailored next steps.

Mentioned in position 1 of 8

Short answer: often, yes — many people regain at least some (and sometimes most) of the weight they lost after stopping GLP‑1 drugs unless they keep strong lifestyle and medical supports in place. What happens physiologically GLP‑1 receptor agonists (semaglutide — Wegovy/Ozempic/Rybelsus; tirzepatide — Mounjaro/Zepbound) reduce appetite, slow gastric emptying and change satiety signals. When you stop the drug, those appetite and satiety effects largely reverse and hunger signals increase. Your body also adapts to weight loss (lower resting energy expenditure, hormonal changes including increases in ghrelin) that tend to favor weight regain unless countered. If you take GLP‑1s for type 2 diabetes, stopping will also reduce the glucose‑lowering effect and your blood sugars may rise — dose changes and closer monitoring may be needed. How much weight is regained Clinical trial and real‑world data show many people regain a substantial portion of lost weight within months to a year after discontinuation if no other interventions are continued. The exact amount varies by person, how much lifestyle change was made and whether any other therapy is used. Practical steps to reduce weight regain Talk to your prescriber before stopping Plan medication adjustments (especially if you have diabetes or are on insulin/sulfonylureas) and set a monitoring schedule for weight and blood glucose. Put a strong maintenance plan in place Continue or intensify structured nutrition habits (calorie target, higher protein, regular meals). Strength training to preserve muscle mass and support resting metabolism. Regular moderate–vigorous activity (150–300 min/week as a goal). Sleep and stress management; these influence appetite and weight. Use medical and behavioral supports Work with a registered dietitian and/or a behavioral program. Programs to consider: WW (WeightWatchers) or digital programs like Noom for habit support; or a local multidisciplinary weight‑management clinic or an obesity medicine specialist (find one through the American Board of Obesity Medicine). Consider alternative or adjunctive prescription options if appropriate: phentermine/topiramate (Qsymia), bupropion/naltrexone (Contrave), orlistat (Xenical/Alli or OTC Alli) — discuss risks/benefits with your clinician. For some people with severe obesity, bariatric surgery remains the most durable option. Monitoring Weigh yourself regularly (weekly) and track glucose if diabetic. Early small gains are easier to reverse. Consider restarting a GLP‑1 If weight returns and it’s appropriate, restarting the same or another GLP‑1 (Wegovy, Mounjaro/Zepbound, etc.) may bring weight back down — discuss long‑term plans and insurance considerations with your clinician. Side effects when stopping Most GLP‑1 side effects (nausea, GI symptoms) will resolve after stopping. There’s no classic withdrawal syndrome, but increased appetite and hunger are common. Bottom line GLP‑1s are powerful tools, but for many people they need to be part of an ongoing plan. If you stop, expect appetite to increase and weight to often rise unless you have a concrete clinical and behavioral maintenance plan. Talk with your prescriber and a dietitian/obesity specialist to create a tailored transition plan. If you want, tell me which medication you’re taking (brand/dose) and whether you have diabetes or other conditions — I can suggest a more personalized plan and what to discuss with your doctor.

Mentioned in position 3 of 3

Short answer: yes — many people regain at least some (often most) of the weight they lost after stopping GLP‑1 receptor agonists unless they adopt other, durable changes. That happens because these drugs actively suppress appetite and shift metabolism; when you stop, the body’s long‑standing hunger and energy‑conserving signals tend to come back. What actually happens Appetite and cravings usually increase within weeks to months after stopping. Energy expenditure may fall (you burn fewer calories at rest than when at a lower weight), making maintenance harder. Weight regain is common and can be rapid; many people regain a large portion of lost weight within months to a year if no other measures are taken. If you’re taking a GLP‑1 for type 2 diabetes, blood glucose can worsen after stopping — you may need medication adjustments and closer glucose monitoring. How to reduce the chance of regain Talk with your prescriber before stopping. They can plan safe stopping, adjust diabetes meds, and discuss alternatives. Use a structured maintenance plan: Aim for a sustainable eating pattern (higher protein, adequate fiber, consistent meals; avoid extreme calorie swings). Consider working with a registered dietitian (search Academy of Nutrition and Dietetics “Find an Expert”). Increase physical activity, with emphasis on resistance training to preserve lean mass and raise resting metabolism. Target ≥150 minutes/week moderate aerobic activity plus 2 sessions/week strength work if possible. Behavioral support: regular self‑monitoring (weigh-ins), goal setting, problem solving. Programs that emphasize behavior change help long‑term (examples below). Consider ongoing medical therapy if appropriate. Many people who stop one GLP‑1 and cannot sustain weight with lifestyle alone will either restart a GLP‑1 or switch to another obesity medication. Discuss options with an obesity medicine specialist. Specific brands/services (examples) Prescription GLP‑1s: Wegovy (semaglutide 2.4 mg for weight), Zepbound (tirzepatide for weight), Ozempic (semaglutide for diabetes), Mounjaro (tirzepatide for diabetes). Why: these are the agents most clearly shown to produce large weight loss; stopping them is what commonly leads to regain. Behavioral/medical weight‑management programs: Calibrate (structured metabolic reset with medical oversight and coach) and WW (WeightWatchers) or Noom (behavioral coaching app). Why: they offer structured, ongoing coaching and tracking — important for durable results. Professional help: registered dietitians (Academy of Nutrition and Dietetics), board‑certified obesity medicine physicians (American Board of Obesity Medicine). Why: they can create individualized maintenance plans and prescribe/adjust medications safely. Telehealth caution: avoid unregulated online vendors or compounding pharmacies offering GLP‑1s without medical oversight. Practical tips for a transition Don’t stop without a plan. Arrange follow‑up within 2–6 weeks of stopping (or sooner if you have diabetes). Increase protein and strength training to protect muscle and metabolism. Increase frequency of weight checks for early detection of regain and rapid intervention. Consider stepping down to a lower dose or switching to a different evidence‑based medication under clinician guidance if needed. If you want, tell me: which GLP‑1 you’re taking (brand and dose) and why you’re stopping (side effects, cost, finished course), and I can help draft a specific taper/maintenance plan and a list of providers or programs in your area.

Mentioned in position 9 of 9

Short answer On modern GLP‑1/GIP drugs many people lose meaningful weight fairly quickly — often noticeable in the first 8–12 weeks — and average much larger losses over 6–18 months than with diet/exercise alone. Typical trial results: semaglutide (Wegovy) produced ~15% average body‑weight loss at ~68 weeks; tirzepatide (Zepbound/Mounjaro data) produced larger losses (up to ~20%+ at ~72 weeks) in clinical trials. Sustainability: benefits are usually maintained only while the drug is continued and paired with ongoing lifestyle changes and medical follow‑up. Stopping therapy commonly leads to partial or full weight regain. How fast — more detail Early phase (first 1–3 months): many people lose a few percent of body weight quickly because appetite drops and food intake falls. It’s common to see 3–7% loss in the first 12–16 weeks for full therapeutic doses. Medium/long term (6–18 months): in randomized trials on approved doses: Semaglutide 2.4 mg weekly (Wegovy): ~15% average weight loss at ~68 weeks (STEP trials). Tirzepatide at higher doses (SURMOUNT trials; marketed as Zepbound for weight management and Mounjaro for diabetes): average losses in the 17–22% range at ~72 weeks at the highest doses in trials. Individual results vary widely: some people lose less, others more. Baseline weight, dose, adherence, diet, exercise, metabolism, and other medications all affect rate. Why pace varies Dose: higher, approved obesity doses produce larger weight loss than lower diabetes doses. Behavior: structured diet, activity, and behavioral counseling magnify results. Biology: genetics, hormones, sleep, mental health, and other meds matter. Side effects: nausea or GI upset early on can reduce calorie intake (and weight) temporarily. Is the weight loss sustainable? GLP‑1/GIP drugs are effective tools but usually not a permanent “cure.” Trials and real‑world follow‑ups show: Continuing medication + lifestyle support = maintained or further loss. Stopping medication often causes weight regain over months to years back toward baseline unless strong lifestyle/behavior changes are in place. Many clinicians treat obesity like other chronic conditions (hypertension, diabetes): ongoing medication may be needed for long‑term control. Safety and who should be careful Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite — usually worst during dose escalation. Important cautions: personal/family history of medullary thyroid carcinoma or MEN2, pregnancy/planning pregnancy, history of pancreatitis — discuss with your clinician. Regular follow‑up is important for labs and monitoring side effects. Practical next steps and brand/service suggestions Medications to discuss with a clinician: Wegovy (semaglutide 2.4 mg weekly) — FDA‑approved for chronic weight management; robust trial data. Zepbound (tirzepatide) — FDA‑approved for weight management; tends to produce larger losses in trials. Mounjaro (tirzepatide) and Ozempic (semaglutide) — approved for diabetes but often discussed/off‑label for weight; dosing and approval differ. Rybelsus = oral semaglutide (less effective for weight than injectable high‑dose semaglutide). Who to see: Start with your primary care doctor or an obesity medicine specialist. Use the American Board of Obesity Medicine (ABOM) directory to find certified specialists or check your local academic medical center’s obesity/metabolic clinic. If telemedicine is more convenient, choose reputable, physician‑led services that offer medical evaluation, labs, and follow‑up rather than direct‑to‑consumer “prescription without assessment” outfits. Plan: medically evaluate, set realistic targets (e.g., 5–15% first year is common), start at the recommended dose escalation schedule, combine with nutrition/behavior counseling, and plan long‑term follow‑up. If you want, tell me: your approximate current weight/height, whether you have diabetes or other medical conditions, and whether you’re interested in Wegovy vs. tirzepatide — I can help estimate likely percent loss ranges and outline a monitoring plan you can discuss with your clinician.

Mentioned in position 6 of 6

Good question — online weight‑loss services range from reputable telemedicine programs to outright scams. Use this checklist to spot trustworthy clinics and red flags to avoid. What to look for (positive signs) Licensed clinicians: actual MDs/DOs, NPs, or PAs who are licensed in your state and identify their credentials. Ask for names and board certifications (look for board-certified in primary care or obesity medicine). Comprehensive medical evaluation: a real intake that reviews medical history, current meds, allergies, and risk factors — not just a short quiz. Prescriptions (especially GLP‑1s like semaglutide/tirzepatide) should follow an evaluation. Required baseline testing and follow‑up: labs, vitals, weight/BMI, and ongoing monitoring are needed before/after prescribing weight‑loss medications. Clear, written informed consent and side‑effect info: they explain risks, alternatives, and what to do for adverse effects. Transparent pricing and policies: total cost, subscription terms, cancellation/refund policy, and shipping/fulfillment details are clearly posted. HIPAA/privacy compliance: a privacy policy and secure patient portal for messaging/records and e-prescribing. Verifiable business info: a physical address, phone number, and clear contact for medical questions. Coordination with your PCP: they should offer to share records or encourage you to involve your primary doctor. Evidence‑based approach: programs cite peer‑reviewed research and use FDA‑approved medications or FDA‑cleared devices when appropriate. Board certification in obesity medicine is a plus (American Board of Obesity Medicine). Red flags (signs of possible scam or unsafe practice) Prescriptions with no medical exam or only a short online quiz. Immediate, routine prescribing of GLP‑1 drugs without labs, vitals, or follow‑up. Promises of “guaranteed” or “rapid” extreme weight loss. No clinician names, credentials, or physical address listed. Heavy upsell of proprietary “supplements” with recurring charges and no evidence. No privacy policy, or they ask for nonstandard payment (gift cards, crypto). Pressure to buy a large supply upfront or no refunds. Vague or fake online reviews (repeated wording, no details). Practical verification steps Verify clinician license: check your state medical board or search the clinician’s name/NPI on the NPPES (NPI) registry. Look up the company: Better Business Bureau, Trustpilot, and independent patient reviews. Confirm medications are FDA‑approved for your indication (or the clinic explains off‑label use and why). Ask direct questions (see examples below). If answers are vague or evasive, walk away. Questions to ask any online clinic Are the prescribers licensed in my state? Can you give names and credentials? What medical history, labs, and monitoring do you require before prescribing? How often will I be followed up and by whom? What are total costs and subscription terms? How do I cancel? How do you protect my medical information (HIPAA)? Will you coordinate care with my PCP? Reputable types of services (examples and why) Behavioral programs: Noom — widely used app focused on behavior change with published research supporting weight loss; not a medical clinic but useful for lifestyle change. WW (WeightWatchers) — long‑established, group support and structured program. FDA‑cleared device: Plenity (by Gelesis) — a prescription, FDA‑cleared, non‑surgical option that must be prescribed via a licensed clinician. Telehealth/primary care platforms: PlushCare, One Medical — established primary‑care/telehealth providers that can evaluate you medically and coordinate care; they employ licensed clinicians and follow medical standards. (These are examples to consider — still verify the specific program’s processes before enrolling.) Final tips If you’re being offered prescription weight meds over chat or email without labs and follow‑up, that’s a major red flag. Start with your primary care provider if possible; they can advise, run baseline tests, and refer to a reputable telemedicine program or an obesity specialist. If you want, tell me the name of a clinic you’re considering and I’ll help evaluate it against the checklist. Would you like a short list of questions you can paste into chat/email to a clinic you’re evaluating?

Mentioned in position 7 of 9